RDInvesting Provides Investors with Free In-Depth Equity Reports on MDVN, MELI, RMD and WLK


Follow this company

Companies Mentioned

NASDAQ:MDVN / NASDAQ:MELI / NYSE:RMD / NYSE:WLK
03/03/2014 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Medivation Inc. (NASDAQ: MDVN) shares fell 14.92 percent to close at $71.91 a share Friday. The stock traded between $70.87 and $75.98 on volume of 8.02 million shares traded. Analysts at Cowen have recently downgraded the company’s rating to “underperform” from “market perform”. Shares of Medivation have fallen approximately 2.5 percent year-to-date.

Find out more about Medivation including full access to the free equity report at:        
www.RDInvesting.com/MDVN

Mercadolibre Inc. (NASDAQ: MELI) shares increased 10.56 percent to close at $104.18 a share Friday. The stock traded between $100.24 and $112.88 on volume of 3.99 million shares traded. Analysts at Stifel have recently upgraded the company’s rating to “buy” from “sell”. Shares of Mercadolibre have fallen approximately 3.0 percent year-to-date.

Find out more about Mercadolibre including full access to the free equity report at:     
www.RDInvesting.com/MELI

ResMed Inc. (NYSE: RMD) shares declined 0.43 percent to close at $44.02 a share Friday. The stock traded between $43.28 and $44.95 on volume of 1.89 million shares traded. Analysts at Macquarie have recently upgraded the company’s rating to “outperform” from “neutral”. Shares of ResMed have fallen approximately 6.0 percent year-to-date.

Find out more about ResMed including full access to the free equity report at:       
www.RDInvesting.com/RMD

Westlake Chemical Corporation (NYSE: WLK) shares increased 0.79 percent to close at $133.33 a share Friday. The stock traded between $132.82 and $135.84 on volume of 495,450 shares traded. Analysts at JPMorgan have recently upgraded the company’s rating to “buy” from “neutral”. Shares of Westlake Chemical have gained approximately 9.0 percent year-to-date.

Find out more about Westlake Chemical including full access to the free equity report at:       
www.RDInvesting.com/WLK

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:               
Research Driven Investing                
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *